SOLIRIS® - (Eculizumab) Products

SOLIRIS® (eculizumab) is a first-in-class terminal complement inhibitor which works by electively inhibiting activation of specific proteins in the complement system (c5 and c5b), which play a role in the treatment of multiple rare diseases.1

Nufactor carries SOLIRIS® (Eculizumab):

FDA-Approved Indication
Product: SOLIRIS® (Eculizumab)
Manufacturer: Alexion
FDA-Approved Indication: Generalized myasthenia gravis (gMG),
Paroxysmal nocturnal hemoglobinuria (PNH),
Atypical hemolytic uremic syndrome (aHUS),
Neuromyelitis optica spectrum disorder (NMOSD)

1 Alexion Pharmaceuticals. Soliris® (Eculizumab).

Click here for a SOLIRIS (Eculizumab) order form

Contact Nufactor

At Nufactor, we are committed to providing our patients the education, support and resources necessary to complete your IVIG treatment successfully and with the desired outcomes. Please contact us with any further questions.